Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Structural insight into recognition of Clostridioides difficile toxin A by novel neutralizing nanobodies targeting QTIN-like motifs within its receptor-binding domain.
Sluchanko NN, Sokolova IV, Favorskaya IA, Esmagambetov IB, Tukhvatulin AI, Alekseeva IA, Ungur AS, Varfolomeeva LA, Boyko KM, Logunov DY, Gintsburg AL, Popov VO, Shcheblyakov DV, Belyi YF. Sluchanko NN, et al. Among authors: shcheblyakov dv. Int J Biol Macromol. 2024 Dec;283(Pt 4):137910. doi: 10.1016/j.ijbiomac.2024.137910. Epub 2024 Nov 20. Int J Biol Macromol. 2024. PMID: 39577542
Immunogenicity and Protectivity of Sputnik V Vaccine in hACE2-Transgenic Mice against Homologous and Heterologous SARS-CoV-2 Lineages Including Far-Distanced Omicron BA.5.
Dolzhikova IV, Tukhvatulin AI, Grousova DM, Zorkov ID, Komyakova ME, Ilyukhina AA, Kovyrshina AV, Shelkov AY, Botikov AG, Samokhvalova EG, Reshetnikov DA, Siniavin AE, Savina DM, Shcheblyakov DV, Izhaeva FM, Dzharullaeva AS, Erokhova AS, Popova O, Ozharovskaya TA, Zrelkin DI, Goldovskaya PP, Semikhin AS, Zubkova OV, Nedorubov AA, Gushchin VA, Naroditsky BS, Logunov DY, Gintsburg AL. Dolzhikova IV, et al. Among authors: shcheblyakov dv. Vaccines (Basel). 2024 Oct 8;12(10):1152. doi: 10.3390/vaccines12101152. Vaccines (Basel). 2024. PMID: 39460319 Free PMC article.
Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding Domain.
Sluchanko NN, Shcheblyakov DV, Varfolomeeva LA, Favorskaya IA, Dolzhikova IV, Korobkova AI, Alekseeva IA, Esmagambetov IB, Derkaev AA, Prokofiev VV, Zorkov ID, Logunov DY, Gintsburg AL, Popov VO, Boyko KM. Sluchanko NN, et al. Among authors: shcheblyakov dv. Biochemistry (Mosc). 2024 Jul;89(7):1260-1272. doi: 10.1134/S0006297924070083. Biochemistry (Mosc). 2024. PMID: 39218023 Free article.
Broadly Reactive Nanobody Targeting the H3 Hemagglutinin of the Influenza A Virus.
Shcheblyakov DV, Voronina DV, Favorskaya IA, Esmagambetov IB, Alekseeva IA, Korobkova AI, Ryabova EI, Derkaev AA, Kan VY, Dzharullaeva AS, Tukhvatulin AI, Bandelyuk AS, Shmarov MM, Logunov DY, Gintsburg AL. Shcheblyakov DV, et al. Acta Naturae. 2024 Jan-Mar;16(1):101-110. doi: 10.32607/actanaturae.27374. Acta Naturae. 2024. PMID: 38698957 Free PMC article.
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period.
Fomina DS, Lebedkina MS, Iliukhina AA, Kovyrshina AV, Shelkov AY, Andreev SS, Chernov AA, Dolzhikova IV, Kruglova TS, Andrenova GV, Tukhvatulin AI, Shcheblyakov DV, Karaulov AV, Lysenko MA, Logunov DY, Gintsburg AL. Fomina DS, et al. Among authors: shcheblyakov dv. Front Immunol. 2023 Oct 20;14:1259725. doi: 10.3389/fimmu.2023.1259725. eCollection 2023. Front Immunol. 2023. PMID: 37928549 Free PMC article. Clinical Trial.
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study.
Tukhvatulin AI, Dolzhikova IV, Dzharullaeva AS, Grousova DM, Kovyrshina AV, Zubkova OV, Zorkov ID, Iliukhina AA, Shelkov AY, Erokhova AS, Popova O, Ozharovskaia TA, Zrelkin DI, Izhaeva FM, Shcheblyakov DV, Esmagambetov IB, Tokarskaya EA, Nikitenko NA, Lubenets NL, Khadorich EA, Gushchin VA, Borzakova SN, Vlasova AV, Osmanov IM, Gorev VV, Naroditsky BS, Logunov DY, Gintsburg AL. Tukhvatulin AI, et al. Among authors: shcheblyakov dv. Front Immunol. 2023 Aug 1;14:1228461. doi: 10.3389/fimmu.2023.1228461. eCollection 2023. Front Immunol. 2023. PMID: 37600800 Free PMC article. Clinical Trial.
rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19.
Esmagambetov IB, Ryabova EI, Derkaev AA, Shcheblyakov DV, Dolzhikova IV, Favorskaya IA, Grousova DM, Dovgiy MA, Prokofiev VV, Gosudarev AI, Byrikhina DV, Zorkov ID, Iliukhina AA, Kovyrshina AV, Shelkov AY, Naroditsky BS, Logunov DY, Gintsburg AL. Esmagambetov IB, et al. Among authors: shcheblyakov dv. Front Immunol. 2023 Mar 30;14:1129245. doi: 10.3389/fimmu.2023.1129245. eCollection 2023. Front Immunol. 2023. PMID: 37063833 Free PMC article.
Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A.
Panova EA, Kleymenov DA, Shcheblyakov DV, Bykonia EN, Mazunina EP, Dzharullaeva AS, Zolotar AN, Derkaev AA, Esmagambetov IB, Sorokin II, Usachev EV, Noskov AN, Ivanov IA, Zatsepin TS, Dmitriev SE, Gushchin VA, Naroditsky BS, Logunov DY, Gintsburg AL. Panova EA, et al. Among authors: shcheblyakov dv. Front Immunol. 2023 Feb 14;14:1098302. doi: 10.3389/fimmu.2023.1098302. eCollection 2023. Front Immunol. 2023. PMID: 36865543 Free PMC article.
Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level.
Godkov MA, Ogarkova DA, Gushchin VA, Kleymenov DA, Mazunina EP, Bykonia EN, Pochtovyi AA, Shustov VV, Shcheblyakov DV, Komarov AG, Tsibin AN, Zlobin VI, Logunov DY, Gintsburg AL. Godkov MA, et al. Among authors: shcheblyakov dv. Vaccines (Basel). 2022 Dec 30;11(1):90. doi: 10.3390/vaccines11010090. Vaccines (Basel). 2022. PMID: 36679936 Free PMC article.
Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus.
Gushchin VA, Ogarkova DA, Dolzhikova IV, Zubkova OV, Grigoriev IV, Pochtovyi AA, Iliukhina AA, Ozharovskaia TA, Kuznetsova NA, Kustova DD, Shelkov AY, Zrelkin DI, Odintsova AS, Grousova DM, Kan VY, Davtyan SA, Siniavin AE, Belyaeva ED, Botikov AG, Bessonova AA, Vasilchenko LA, Vasina DV, Kleymenov DA, Slutskiy EA, Tkachuk AP, Burgasova OA, Loginova SY, Rozhdestvensky EV, Shcheblyakov DV, Tsibin AN, Komarov AG, Zlobin VI, Borisevich SV, Naroditsky BS, Logunov DY, Gintsburg AL. Gushchin VA, et al. Among authors: shcheblyakov dv. Front Immunol. 2022 Nov 16;13:1023164. doi: 10.3389/fimmu.2022.1023164. eCollection 2022. Front Immunol. 2022. PMID: 36466896 Free PMC article.
39 results